Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

In many cases, there is a difference for adults and children: RSV is a virus that ... According to the Cleveland Clinic, ...

The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results of ziresovir, a novel RSV-targeted ...

Coinfection with RSV, REV, and MPV was significantly associated with treatment failure and prolonged treatment in children with viral LRTIs on respiratory support.

In this cohort study of children hospitalized with respiratory syncytial virus (RSV) in 2022 and 2023, severe RSV disease was more likely among those age 2 or older with pulmonary and neurologic, ...

It is estimated that an average of 33 children under five years old die from RSV in the UK each year 7. There is no effective specific drug treatment for RSV and as a result, the mainstay of ...

Affecting the airways and lungs, RSV is a life-threatening virus responsible for sending 3.6 million children to hospitals worldwide each year. It is especially dangerous for vulnerable young ...

The market for RSV treatments currently has only one ... Over the next decade, the market could expand to reach at-risk adults and children suffering acute infections, probably through the ...

A multifaceted educational intervention program may have been somewhat effective in modifying physicians' prescribing habits for the treatment of RSV lower-respiratory-tract infection. Presented ...